Skip to main content

Table 3 Factors associated with APRI score >1.5

From: HCV co-infection and markers of liver injury and fibrosis among HIV-positive childbearing women in Ukraine: results from a cohort study

 

Proportion with APRI >1.5 (significant fibrosis)

Odds ratio

(n = 726)

p value

Adjusted odds ratio (n = 726)

p value

Hepatitis C antibody status

 Negative

2.1% (11/531)

1.00

 

1.00

 

 Positive

10.0% (23/231)

5.16 (2.50-10.65)

<0.001

2.53 (1.03-6.23)

0.044

Hepatitis B surface antigen

 Positive

1.4% (2/146)

1.00

 

1.00

 

 Negative

5.2% (32/616)

3.28 (0.89-12.02)

0.074

3.28 (0.85-12.71)

0.085

History of injecting drug use

 No

1.8% (11/603)

1.00

 

1.00

 

 Yes

15.3% (23/150)

9.15 (4.40-19.01)

<0.001

3.51 (1.39-8.89)

0.008

WHO stagea

 1–2

2.6% (16/605)

1.00

 

1.00

 

 3–4

12.4% (18/145)

5.02 (2.52-10.02)

<0.001

3.47 (1.51-7.99)

0.003

CD4 counta

  > 350 cells/mm3

3.9% (22/563)

1.00

   

 201-350 cells/mm3

5.3% (7/132)

1.46 (0.62-3.42)

0.381

  

  ≤ 200 cells/mm3

8.2% (4/49)

2.32 (0.80-6.67)

0.119

  

Smoker at postnatal cohort enrolment

 No

2.7% (11/409)

1.00

 

1.00

 

 Yes, current smoker

6.8% (23/340)

2.59 (1.26-5.33)

0.010

1.06 (0.46-2.42)

0.896

Age

 Per increasing year

 

1.10 (1.03-1.18)

0.007

1.08 (0.99-1.18)

0.070

Postnatal ARTb

 Yes

4.0% (10/253)

1.00

 

1.00

 

 No

4.8% (24/500)

1.15 (0.55-2.41)

0.715

3.08 (1.23-7.74)

0.017

  1. aClosest to timing of liver function test measures bAt postnatal cohort enrolment